The Effect of Simvastatin on the Dynamics of NF-κB-Regulated Neurodegenerative and Neuroprotective Processes in the Acute Phase of Ischemic Stroke
Open Access
- 19 May 2023
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 60 (9) , 4935-4951
Abstract
Statins are lipid-lowering drugs that act by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, a rate-limiting enzyme in cholesterol biosynthesis. Animal studies have shown neuroprotective effects of statins in cerebral stroke. However, the underlying mechanisms are not fully understood. The nuclear factor-kappa B (NF-κB) transcription factor is involved in the regulation of apoptosis in stroke. Different dimers of NF-κB regulate the gene expression of proteins involved in both neurodegeneration and neuroprotection. We aimed to determine whether simvastatin improves stroke outcome via inhibition of the RelA/p65-containing subunit and downregulation of stroke-induced pro-apoptotic genes or via activation of NF-κB dimers containing the c-Rel subunit and upregulation of anti-apoptotic genes during the acute stroke phase. Eighteen-month-old Wistar rats, subjected to permanent MCAO or sham surgery, were administered simvastatin (20 mg/kg b.w.) or saline for 5 days before the procedure. Stroke outcome was determined by measuring cerebral infarct and assessing motor functions. The expression of NF-κB subunits in various cell populations was investigated using immunofluorescence/confocal microscopy. RelA and c-Rel were detected by WB. The NF-κB-DNA binding activity was investigated using EMSA, and expression of Noxa, Puma, Bcl-2, and Bcl-x genes was analyzed by qRT-PCR. Results showed a 50% infarct size reduction and significant motor function improvement in the simvastatin-treated animals which correlated with a decrease in RelA and a transient increase in the c-Rel level in the nucleus, normalization of the NF-κB-DNA binding activity, and downregulation of the NF-κB-regulated genes. Our results provide new insights into the statin-mediated neuroprotective action against stroke based on NF-κB pathway inhibition.Keywords
Funding Information
- Ministry of Education and Science (ST-11)
- MUG (W-197)
This publication has 81 references indexed in Scilit:
- Preclinical stroke research – advantages and disadvantages of the most common rodent models of focal ischaemiaBritish Journal of Pharmacology, 2011
- In vivo Contributions of BH3-Only Proteins to Neuronal Death Following Seizures, Ischemia, and Traumatic Brain InjuryJournal of Cerebral Blood Flow & Metabolism, 2011
- Nuclear factor-κB is a critical mediator of stress-impaired neurogenesis and depressive behaviorProceedings of the National Academy of Sciences, 2010
- Delayed treatment with a p53 inhibitor enhances recovery in stroke brainAnnals of Neurology, 2009
- c-Rel, an NF-κB family transcription factor, is required for hippocampal long-term synaptic plasticity and memory formationLearning & Memory, 2008
- NF-κB/Rel Regulates Inhibitory and Excitatory Neuronal Function and Synaptic PlasticityMolecular and Cellular Biology, 2006
- Regulation of p53 tumour suppressor target gene expression by the p52 NF‐κB subunitThe EMBO Journal, 2006
- PLEIOTROPIC EFFECTS OF STATINSAnnual Review of Pharmacology and Toxicology, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Activators and target genes of Rel/NF-κB transcription factorsOncogene, 1999